Phase II Multicenter Study of Induction Chemotherapy Followed by Concurrent Efaproxiral (RSR13) and Thoracic Radiotherapy for Patients With Locally Advanced Non–Small-Cell Lung Cancer
| Autor: | Harvey Kreisman, Larry Kleinberg, Abdenour Nabid, Solomon Hamburg, Walter J. Curran, William Spanos, Luis Souhami, Wilson Roa, Hak Choy, Baldassarre Stea, Joseph Ayoub, Pablo J. Cagnoni, Charles E. Scott, Colum Smith, Adam P. Boyd |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Radiation-Sensitizing Agents Cancer Research medicine.medical_specialty Lung Neoplasms Paclitaxel medicine.medical_treatment Urology Carboplatin chemistry.chemical_compound Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Infusions Intravenous Lung cancer Survival analysis Aged Chemotherapy Aniline Compounds business.industry Area under the curve Induction chemotherapy Middle Aged medicine.disease Combined Modality Therapy Survival Analysis Radiation therapy Oncology chemistry Efaproxiral Female Propionates business Nuclear medicine medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 23:5918-5928 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2005.08.011 |
| Popis: | Purpose Efaproxiral (RSR13) reduces hemoglobin oxygen–binding affinity, facilitates oxygen release, and increases tissue pO2. We conducted a phase II multicenter study that assessed the efficacy and safety of efaproxiral when administered with thoracic radiation therapy (TRT), following induction chemotherapy, for treatment of locally advanced non–small-cell lung cancer (NSCLC). Patients and Methods Fifty-one patients with locally advanced NSCLC were enrolled at 13 sites. Treatment comprised two cycles of paclitaxel (225 mg/m2) and carboplatin (area under the curve, 6), 3 weeks apart, followed by TRT (64 Gy/32 fractions) with concurrent efaproxiral (50 to 100 mg/kg). Survival results were compared with results of study Radiation Therapy Oncology Group (RTOG) 94-10. Results Overall response rate was 75% (37 of 49 patients). Complete and partial response rates were 6% (three of 49 patients) and 69% (34 of 49 patients), respectively. Median survival time (MST) was 20.6 months (95% CI, 14.0 to 24.2); overall survival rates at 1- and 2-years were 67% and 37%, respectively. Survival results were compared with the sequential (S-CRT) and concurrent (C-CRT) chemoradiotherapy arms of RTOG 94-10. MSTs for cases matched by stage, Karnofsky performance status, and age were: RT-010, 20.6 months; S-CRT, 15.1 months; and C-CRT, 17.9 months. Grade 3 to 4 toxicities related to efaproxiral that occurred in more than one patient included transient hypoxemia (19%), radiation pneumonitis (11%), and fatigue (4%). Conclusion Addition of efaproxiral to S-CRT represents a promising approach in NSCLC treatment, and a randomized study should be pursued. The low incidence of grade 3 to 4 toxicities suggests that the use of efaproxiral instead of a cytotoxic agent, as a radiation sensitizer, may be advantageous. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|